Global Expansion of LAL Reagents Using Recombinant Technology
First written in FY2019. 5 of 11 entries say "Advanced", first in FY2021. Latest entry: FY2026.
No other company in this theme has enough history to compare yet.
- FY2026AchievedAnnual report
「In cooperation with our overseas subsidiary, Associates of Cape Cod, Inc., we achieved growth in the LAL business by accelerating the rollout of reagents for endotoxin testing and in vitro diagnostic products for glucan testing.」
The company concluded that it had achieved growth in the LAL business through the accelerated rollout of recombinant reagents and other products, identified as a priority initiative in its medium-term management plan. - 2026-05-13AchievedEarnings
「We achieved the expansion of the LAL business through recombinant technology.」
The company concluded that its priority measures for expanding the LAL business had been achieved. - FY2025AdvancedAnnual report
「Marking ACC's 50th anniversary and looking ahead to the next 50 years, the company renewed its brand identity as a solutions company using recombinant DNA technology.」
The company renewed its brand identity as a solutions company using recombinant DNA technology, moving beyond the sale of recombinant reagents. - FY2025-H1AdvancedAnnual report
「Revenue was ¥5,863 million, up 18.0% year on year. Revenue increased year on year due to the positive foreign-exchange effect at overseas subsidiary Associates of Cape Cod, Inc., higher sales of glucan-testing in vitro diagnostic products and the recombinant endotoxin-testing reagent PyroSmart NextGen, and strong domestic sales.」
Increased sales of PyroSmart NextGen, a recombinant reagent for endotoxin testing, were reported, and total LAL business revenue increased 18.0% year on year. - FY2024AdvancedAnnual report
「Continue accumulating scientific data on PyroSmart NextGen, a recombinant reagent for endotoxin testing, and publish papers jointly with our overseas subsidiary, Associates of Cape Cod, Inc. • For in vitro diagnostic products for glucan testing, expand the countries where they are sold and develop new hospital-market opportunities」
For the rollout of recombinant reagents, the company advanced the accumulation of scientific data and joint publication of papers with its overseas subsidiary. For in vitro diagnostic products for glucan testing, it moved to the stage of expanding the countries where they are sold and developing new hospital-market opportunities. - FY2023-Q3RaisedAnnual report
「In cooperation with our overseas subsidiary, Associates of Cape Cod, Inc., we will use PyroSmart NextGen, a recombinant reagent for endotoxin testing, to accumulate reliable scientific data and promote the development of new diagnostic reagents using recombinant DNA technology. We also aim to create new value by developing and improving measuring instruments and software in collaboration with related companies.」
The scope of the initiatives was expanded from the global rollout of recombinant reagents to the accumulation of scientific data and the development and improvement of new diagnostic reagents, measuring instruments and software. - FY2022-Q1AdvancedAnnual report
「Sales of PyroSmart NextGen, a recombinant reagent for endotoxin testing, began at Associates of Cape Cod, Inc. in April 2021 and at our company in May of the same year.」
For the recombinant reagent for endotoxin testing, sales began at the overseas subsidiary in April, followed by the launch of sales by our company in May. - FY2021AdvancedAnnual report
「In addition, in April 2021, our overseas subsidiary, Associates of Cape Cod, Inc., launched PyroSmart NextGen, a recombinant reagent for endotoxin testing.」
The global rollout of recombinant reagents for endotoxin testing reached the stage at which the overseas subsidiary had launched PyroSmart NextGen and was proceeding with global expansion, including in Japan. - FY2020-Q3RestatedAnnual report
「At Associates of Cape Cod, Inc., our overseas subsidiary responsible for the Group's international LAL business, we will pursue the global rollout of recombinant reagents for endotoxin testing, whose use is expected to spread in the future, thereby establishing a new earnings base.」
The company continues to pursue the initiative of establishing a new earnings base for the LAL business through the global rollout of recombinant reagents for endotoxin testing. - FY2020-Q2RestatedAnnual report
「At Associates of Cape Cod, Inc., our overseas subsidiary responsible for the Group's international LAL business, we will pursue the global rollout of recombinant reagents for endotoxin testing, whose use is expected to spread in the future, thereby establishing a new earnings base.」
The company has reiterated as a priority initiative its plan to establish a new earnings base for the LAL business through the global rollout of recombinant reagents for endotoxin testing. - FY2019First statedAnnual report
「In the LAL business, we will accelerate the global rollout of reagents for endotoxin testing that use recombinant DNA technology.」
As a new growth initiative under the next plan for the LAL business, the company identified for the first time the accelerated global rollout of reagents using recombinant DNA technology.